Okyo Pharma to present at two European ophthalmology industry events in September 2026

OKYO Pharma Limited (Nasdaq: OKYO) announced on September 9, 2026 that it will present at the Ophthalmology Futures European Forum and the 5th Annual ESCRS iNovation Day. The company is a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases.¹

The Ophthalmology Futures Forum takes place September 10 in London, described as an event where clinical innovators, investors, and industry leaders convene to examine what's next in ophthalmology and where the next wave of value will be created.¹ ESCRS iNovation Day follows on September 11, 2026 at ExCeL London, held alongside the 44th Congress of the ESCRS, which runs September 11 through 15, 2026. The event is recognized as a cornerstone event for ophthalmic innovation in Europe, bringing together ophthalmologists, industry leaders, emerging companies and the financial community.¹

OKYO said its participation is tied to its work advancing urcosimod, described as its lead drug candidate, which is being studied in the Phase 3 pivotal "NEPTUNE" trial for NCP.

The company also referenced two recent developments: feedback from an FDA Type D meeting, which it said supported its regulatory and clinical direction for urcosimod, and the filing of its Annual Report, which it said showed a strengthened cash position.

Separately, OKYO's company description states that it plans to initiate a global Phase 3 pivotal clinical trial in the second half of this year, enrolling approximately 111 patients to evaluate a single-dose regimen of urcosimod for the treatment of NCP.¹

The filing was signed by Chief Financial Officer Keeren Shah on September 9, 2026.